CytomX Therapeutics, Inc.
NASDAQ:CTMX
1 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 101.214 | 53.163 | 69.573 | 100.362 | 57.489 | 59.502 | 71.623 | 15.043 | 7.712 | 5.077 | 0.888 |
| Cost of Revenue
| 2.175 | 5.856 | 5.839 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 99.039 | 47.307 | 63.734 | 100.362 | 57.489 | 59.502 | 71.623 | 15.043 | 7.712 | 5.077 | 0.888 |
| Gross Profit Ratio
| 0.979 | 0.89 | 0.916 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 75.651 | 111.649 | 114.194 | 112.936 | 131.619 | 103.866 | 92.277 | 54.755 | 28.357 | 28.302 | 10.89 |
| General & Administrative Expenses
| 30.018 | 42.849 | 39.16 | 36.031 | 36.765 | 33.51 | 25.605 | 19.874 | 12.558 | 6.54 | 4.954 |
| Selling & Marketing Expenses
| -0.146 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 29.872 | 42.849 | 39.16 | 36.031 | 36.765 | 33.51 | 25.605 | 19.874 | 12.558 | 6.54 | 4.954 |
| Other Expenses
| -0.03 | 0.34 | -0.083 | -0.027 | -0.135 | -0.068 | -0.027 | -0.069 | -1.744 | -0.055 | 0.071 |
| Operating Expenses
| 105.523 | 154.498 | 153.354 | 148.967 | 168.384 | 137.376 | 117.882 | 74.629 | 40.915 | 34.842 | 15.844 |
| Operating Income
| -6.484 | -101.335 | -83.781 | -48.605 | -110.895 | -77.874 | -46.259 | -59.586 | -33.203 | -29.765 | -14.956 |
| Operating Income Ratio
| -0.064 | -1.906 | -1.204 | -0.484 | -1.929 | -1.309 | -0.646 | -3.961 | -4.305 | -5.863 | -16.842 |
| Total Other Income Expenses Net
| 9.807 | 2.018 | 0.172 | 1.809 | 8.23 | -0.068 | -0.027 | -0.069 | -1.744 | -0.055 | 0.071 |
| Income Before Tax
| 3.323 | -99.317 | -83.609 | -46.796 | -102.665 | -70.301 | -43.612 | -58.919 | -35.364 | -30.3 | -15.133 |
| Income Before Tax Ratio
| 0.033 | -1.868 | -1.202 | -0.466 | -1.786 | -1.181 | -0.609 | -3.917 | -4.586 | -5.968 | -17.042 |
| Income Tax Expense
| 3.892 | -2.018 | -2.961 | -13.911 | -0.427 | 14.303 | -0.513 | -0.019 | 0.01 | 0.01 | 0.01 |
| Net Income
| -0.569 | -97.299 | -80.648 | -32.885 | -102.238 | -84.604 | -43.099 | -58.9 | -35.374 | -30.31 | -15.143 |
| Net Income Ratio
| -0.006 | -1.83 | -1.159 | -0.328 | -1.778 | -1.422 | -0.602 | -3.915 | -4.587 | -5.97 | -17.053 |
| EPS
| -0.008 | -1.48 | -1.26 | -0.71 | -2.26 | -2.03 | -1.16 | -1.63 | -4.12 | -0.87 | -0.43 |
| EPS Diluted
| -0.008 | -1.48 | -1.26 | -0.71 | -2.26 | -2.03 | -1.16 | -1.63 | -4.12 | -0.87 | -0.43 |
| EBITDA
| -4.309 | -101.335 | -83.781 | -46.032 | -110.895 | -75.99 | -44.614 | -55.497 | -32.426 | -29.03 | -14.224 |
| EBITDA Ratio
| -0.043 | -1.906 | -1.204 | -0.459 | -1.929 | -1.277 | -0.623 | -3.689 | -4.205 | -5.718 | -16.018 |